ISpecimen Ebitda vs Cost Of Revenue Analysis

ISPC Stock

USD 4.29 0.07 1.66%

ISpecimen financial indicator trend analysis is infinitely more than just investigating iSpecimen recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether iSpecimen is a good investment. Please check the relationship between ISpecimen Ebitda and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of iSpecimen Ebitda account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between ISpecimen's Ebitda and Cost Of Revenue is -0.83. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of iSpecimen, assuming nothing else is changed. The correlation between historical values of ISpecimen's Ebitda and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of iSpecimen are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebitda i.e., ISpecimen's Ebitda and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.83

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebitda

Cost Of Revenue

Cost of Revenue is found on iSpecimen income statement and represents the costs associated with goods and services ISpecimen provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from ISpecimen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into iSpecimen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.As of November 29, 2024, Selling General Administrative is expected to decline to about 5.9 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 22.9 M

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.0M	1.2M	2.1M	1.2M
Interest Income	11.4K	169.3K	339.8K	356.7K

Depreciation And Amortization Interest Income

ISpecimen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.67	-0.51	-0.73	0.96	0.91	0.23	-0.47	-0.96	-0.71	0.45	0.92	0.55	-0.77	-0.75	0.98	0.97	-0.79	-0.74	-0.82	-0.5	0.69	0.97	-0.83	0.99	0.58
Short Long Term Debt Total	-0.67		0.76	0.88	-0.85	-0.89	-0.69	0.67	0.72	0.78	-0.68	-0.45	-0.69	0.58	0.62	-0.59	-0.6	0.54	0.55	0.89	-0.22	-0.32	-0.76	0.97	-0.77	-0.86
Other Current Liab	-0.51	0.76		0.89	-0.67	-0.67	-0.42	0.18	0.64	0.4	-0.2	-0.46	-0.37	0.06	0.09	-0.51	-0.35	0.08	0.0	0.56	-0.39	0.17	-0.59	0.77	-0.61	-0.51
Total Current Liabilities	-0.73	0.88	0.89		-0.85	-0.83	-0.45	0.57	0.85	0.51	-0.3	-0.68	-0.43	0.37	0.38	-0.73	-0.57	0.33	0.35	0.7	-0.13	-0.13	-0.77	0.9	-0.8	-0.59
Total Stockholder Equity	0.96	-0.85	-0.67	-0.85		0.98	0.41	-0.56	-0.96	-0.8	0.57	0.82	0.65	-0.75	-0.75	0.92	0.91	-0.76	-0.71	-0.91	-0.26	0.6	0.98	-0.95	0.99	0.74
Net Tangible Assets	0.91	-0.89	-0.67	-0.83	0.98		0.44	-0.56	-0.89	-0.87	0.68	0.72	0.72	-0.77	-0.79	0.84	0.88	-0.78	-0.73	-0.95	-0.2	0.6	0.96	-0.97	0.96	0.85
Property Plant And Equipment Net	0.23	-0.69	-0.42	-0.45	0.41	0.44		-0.53	-0.27	-0.59	0.61	0.02	0.7	-0.35	-0.38	0.09	0.26	-0.34	-0.32	-0.63	0.49	0.18	0.36	-0.58	0.33	0.56
Current Deferred Revenue	-0.47	0.67	0.18	0.57	-0.56	-0.56	-0.53		0.55	0.46	-0.43	-0.38	-0.41	0.65	0.64	-0.43	-0.45	0.5	0.69	0.56	0.09	-0.47	-0.51	0.6	-0.51	-0.46
Net Debt	-0.96	0.72	0.64	0.85	-0.96	-0.89	-0.27	0.55		0.59	-0.31	-0.94	-0.44	0.64	0.62	-0.97	-0.88	0.63	0.62	0.76	0.35	-0.52	-0.93	0.86	-0.97	-0.51
Retained Earnings	-0.71	0.78	0.4	0.51	-0.8	-0.87	-0.59	0.46	0.59		-0.94	-0.39	-0.92	0.85	0.89	-0.56	-0.79	0.89	0.8	0.96	0.15	-0.73	-0.81	0.82	-0.76	-0.94
Accounts Payable	0.45	-0.68	-0.2	-0.3	0.57	0.68	0.61	-0.43	-0.31	-0.94		0.07	0.88	-0.77	-0.83	0.27	0.57	-0.79	-0.74	-0.85	-0.01	0.65	0.57	-0.66	0.51	0.93
Cash	0.92	-0.45	-0.46	-0.68	0.82	0.72	0.02	-0.38	-0.94	-0.39	0.07		0.23	-0.55	-0.5	0.97	0.84	-0.55	-0.53	-0.55	-0.56	0.51	0.83	-0.64	0.88	0.24
Non Current Assets Total	0.55	-0.69	-0.37	-0.43	0.65	0.72	0.7	-0.41	-0.44	-0.92	0.88	0.23		-0.72	-0.76	0.36	0.64	-0.76	-0.67	-0.86	-0.03	0.63	0.71	-0.7	0.61	0.84
Non Currrent Assets Other	-0.77	0.58	0.06	0.37	-0.75	-0.77	-0.35	0.65	0.64	0.85	-0.77	-0.55	-0.72		1.0	-0.66	-0.87	0.98	1.0	0.82	0.55	-0.95	-0.79	0.66	-0.76	-0.71
Other Assets	-0.75	0.62	0.09	0.38	-0.75	-0.79	-0.38	0.64	0.62	0.89	-0.83	-0.5	-0.76	1.0		-0.63	-0.85	0.98	0.99	0.85	0.49	-0.93	-0.79	0.69	-0.75	-0.77
Cash And Short Term Investments	0.98	-0.59	-0.51	-0.73	0.92	0.84	0.09	-0.43	-0.97	-0.56	0.27	0.97	0.36	-0.66	-0.63		0.91	-0.67	-0.64	-0.7	-0.52	0.59	0.91	-0.76	0.95	0.44
Net Receivables	0.97	-0.6	-0.35	-0.57	0.91	0.88	0.26	-0.45	-0.88	-0.79	0.57	0.84	0.64	-0.87	-0.85	0.91		-0.9	-0.84	-0.84	-0.58	0.83	0.95	-0.77	0.95	0.62
Common Stock Total Equity	-0.79	0.54	0.08	0.33	-0.76	-0.78	-0.34	0.5	0.63	0.89	-0.79	-0.55	-0.76	0.98	0.98	-0.67	-0.9		0.96	0.84	0.56	-0.96	-0.81	0.65	-0.77	-0.71
Common Stock Shares Outstanding	-0.74	0.55	0.0	0.35	-0.71	-0.73	-0.32	0.69	0.62	0.8	-0.74	-0.53	-0.67	1.0	0.99	-0.64	-0.84	0.96		0.78	0.57	-0.95	-0.75	0.62	-0.72	-0.66
Non Current Liabilities Total	-0.82	0.89	0.56	0.7	-0.91	-0.95	-0.63	0.56	0.76	0.96	-0.85	-0.55	-0.86	0.82	0.85	-0.7	-0.84	0.84	0.78		0.11	-0.66	-0.89	0.94	-0.87	-0.92
Inventory	-0.5	-0.22	-0.39	-0.13	-0.26	-0.2	0.49	0.09	0.35	0.15	-0.01	-0.56	-0.03	0.55	0.49	-0.52	-0.58	0.56	0.57	0.11		-0.72	-0.39	-0.02	-0.37	0.07
Other Current Assets	0.69	-0.32	0.17	-0.13	0.6	0.6	0.18	-0.47	-0.52	-0.73	0.65	0.51	0.63	-0.95	-0.93	0.59	0.83	-0.96	-0.95	-0.66	-0.72		0.68	-0.44	0.64	0.52
Other Stockholder Equity	0.97	-0.76	-0.59	-0.77	0.98	0.96	0.36	-0.51	-0.93	-0.81	0.57	0.83	0.71	-0.79	-0.79	0.91	0.95	-0.81	-0.75	-0.89	-0.39	0.68		-0.89	0.98	0.71
Total Liab	-0.83	0.97	0.77	0.9	-0.95	-0.97	-0.58	0.6	0.86	0.82	-0.66	-0.64	-0.7	0.66	0.69	-0.76	-0.77	0.65	0.62	0.94	-0.02	-0.44	-0.89		-0.9	-0.84
Net Invested Capital	0.99	-0.77	-0.61	-0.8	0.99	0.96	0.33	-0.51	-0.97	-0.76	0.51	0.88	0.61	-0.76	-0.75	0.95	0.95	-0.77	-0.72	-0.87	-0.37	0.64	0.98	-0.9		0.67
Property Plant And Equipment Gross	0.58	-0.86	-0.51	-0.59	0.74	0.85	0.56	-0.46	-0.51	-0.94	0.93	0.24	0.84	-0.71	-0.77	0.44	0.62	-0.71	-0.66	-0.92	0.07	0.52	0.71	-0.84	0.67

Click cells to compare fundamentals

ISpecimen Account Relationship Matchups

ISpecimen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.2M	6.2M	35.7M	24.6M	15.8M	16.6M
Short Long Term Debt Total	10.6M	12.8M	3.4M	185.8K	196.2K	186.4K
Other Current Liab	2.2M	6.9M	1.0M	1.4M	1.2M	2.1M
Total Current Liabilities	15.8M	22.1M	2.5M	4.3M	6.0M	8.3M
Total Stockholder Equity	(22.7M)	(27.3M)	29.8M	20.3M	9.7M	10.2M
Net Tangible Assets	(25.0M)	(29.9M)	27.1M	15.8M	18.2M	19.1M
Property Plant And Equipment Net	119.9K	75.6K	32.8K	410.5K	321.6K	203.4K
Current Deferred Revenue	2.2M	873.3K	654.7K	132.3K	415.8K	687.7K
Net Debt	10.5M	12.1M	(24.3M)	(15.1M)	(2.1M)	(2.3M)
Retained Earnings	(24.4M)	(29.1M)	(38.0M)	(48.3M)	(59.4M)	(56.4M)
Accounts Payable	737.8K	1.8M	832.7K	2.5M	3.9M	4.1M
Cash	53.9K	695.9K	27.7M	15.3M	2.3M	2.2M
Non Current Assets Total	2.6M	2.7M	2.8M	4.9M	7.6M	4.1M
Cash And Short Term Investments	53.9K	695.9K	27.7M	15.3M	5.0M	9.2M
Net Receivables	1.4M	2.4M	4.9M	3.9M	2.9M	3.0M
Common Stock Shares Outstanding	6.6M	46.8K	408.6K	442.2K	452.1K	429.5K
Liabilities And Stockholders Equity	4.2M	6.2M	35.7M	24.6M	15.8M	16.6M
Other Current Assets	79.2K	417.9K	327.0K	300.4K	292.1K	278.1K
Other Stockholder Equity	(9.5M)	(9.4M)	103.5M	68.6M	69.1M	39.0M
Total Liab	26.9M	33.5M	5.9M	4.3M	6.1M	5.8M
Net Invested Capital	(12.1M)	(14.5M)	33.2M	20.3M	9.7M	10.2M
Property Plant And Equipment Gross	119.9K	75.6K	340.1K	410.5K	766.4K	804.7K
Total Current Assets	1.6M	3.5M	32.9M	19.7M	8.2M	12.5M
Net Working Capital	(14.2M)	(18.7M)	30.4M	15.4M	2.2M	1.1M
Intangible Assets	2.3M	2.6M	2.7M	4.5M	7.2M	3.8M
Property Plant Equipment	119.9K	75.6K	32.8K	410.5K	472.1K	495.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:

How To Invest In ISpecimen

Details

Is ISpecimen Stock a good investment?

Details

What is ISpecimen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(18.12)

Revenue Per Share

19.19

Quarterly Revenue Growth

(0.04)

Return On Assets

(0.44)

Return On Equity

(1.09)

The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ISpecimen Ebitda vs Cost Of Revenue Analysis

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebitda

Cost Of Revenue

ISpecimen fundamental ratios Correlations

ISpecimen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ISpecimen fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Assets	+ 1.0	Non Currrent Assets Other
Common Stock Shares Outstanding	+ 1.0	Non Currrent Assets Other
Net Invested Capital	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Stockholder Equity
Common Stock Shares Outstanding	+ 0.99	Other Assets
Cash And Short Term Investments	+ 0.98	Total Assets

Net Invested Capital	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Total Liab	- 0.97	Net Tangible Assets
Other Current Assets	- 0.96	Common Stock Total Equity
Net Debt	- 0.96	Total Stockholder Equity
Net Debt	- 0.96	Total Assets